Induction of protective Th1 responses to Candida albicans by antifungal therapy alone or in combination with an Interleukin-4 antagonist

Journal of Infectious Diseases

Volumn 176, Issue 1, 1997, Pages 217-226

  Cenci, Elio ^a   Mencacci, Antonella ^a   Del Sero, Giuseppe ^a   Bistoni, Francesco ^a   Romani, Luigina ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANTIFUNGAL AGENT; CANDIDA ANTIGEN; CD4 ANTIGEN; DEOXYCHOLATE SODIUM; FLUCONAZOLE; GAMMA INTERFERON; IMMUNOGLOBULIN E; INTERLEUKIN 12; INTERLEUKIN 4 RECEPTOR; MONOCLONAL ANTIBODY; RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CELLULAR IMMUNITY; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG EFFECT; HELPER CELL; IMMUNOMODULATION; INFECTION RESISTANCE; INOCULATION; INTRAGASTRIC DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0030904791     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/514027     Document Type: Article

References (15)

1. Vartivarian SE, Anaissie EJ, Bodey GP. Emerging fungal pathogens in immunocompromised patients: classification, diagnosis, and management. Clin Infect Dis 1993;17(suppl 2):S481-7.
2. Meunier F. Candidiasis. Eur J Clin Microbiol Infect Dis 1989;8:438-47.
3. Bodey GP. Azole antifungal agents. Clin Infect Dis 1992;14(suppl 1): S161-9.
4. Meyer RD. Current role of therapy with Amphotericin B. Clin Infect Dis 1992;14(suppl 1):S154-60.
5. Graybill JR. Future directions of antifungal chemotherapy. J Infect Dis 1992;14(suppl 1):S170-81.
6. Komshian SV, Uwaydah AK, Sobel JD, Crame LR. Fungemia caused by Candida species and Torulopsis glabrata in hospitalized patients: frequency, characteristics and evaluation of factors influencing outcome. Rev Infect Dis 1989;148:2642-5.
7. Goodman J, Buell D, Gilbert G, for the Seventeen Member Marrow Transplant Study Group. Fluconazole prevents fungal infections in bone marrow transplantation (BMT): results of a placebo-controlled, double-blind, randomized multicenter trial (abstract PS 4.114)). In: Abstracts of the IX Congress of the International Society for Human and Animal Mycology (Montreal). Montreal: JPdL Multi Management, 1991:149.
8. Walsh TJ, Lee JW, Roilides E, et al. Experimental antifungal chemotherapy in granulocytopenic animal models of disseminated candidiasis: approaches to understanding investigational antifungal compounds for patients with neoplastic diseases. Clin Infect Dis 1992;14(suppl 1): S139-47.
9. Hay RJ. Overview of the treatment of disseminated fungal infections. J Antimicrob Chemother 1991;28(suppl B):27-38.
10. van't Wout JW, Mattie H, van Furth R. Comparison of the efficacies of amphotericin B, fluconazole, and itraconazole against a systemic Candida albicans infection in normal and neutropenic mice. Antimicrob Agents Chemother 1989;33:147-51.
11. Domer JE, Lehrer RI. Introduction to Candida. Systemic candidiasis. In: Murphy JW, Friedman H, Bendinelli M, eds. Fungal infections and immune responses. New York: Plenum Press, 1993:49-116.
12. Romani L, Howard DH. Mechanisms of resistance to fungal infections. Curr Opin Immunol 1995;7:517-23.
13. Puccetti P, Romani L, Bistoni F. A Th1-Th2 - like switch in candidiasis: new perspectives for therapy. Trends Microbiol 1995;3:237-40.
14. Romani L, Puccetti P, Bistoni F. Biological role of helper T-cell subsets in candidiasis. Chem Immunol 1996;63:115-37.
15. + subset expression in murine candidiasis. Infect Immun 1992;60: 4950-2.